Cargando…

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use

Background: After stopping serotype 2–containing oral poliovirus vaccine use, serotype 2 poliovirus outbreaks may still occur and require outbreak response supplemental immunization activities (oSIAs). Current oSIA plans include the use of both serotype 2 monovalent oral poliovirus vaccine (mOPV2) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duintjer Tebbens, Radboud J., Thompson, Kimberly M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124926/ https://www.ncbi.nlm.nih.gov/pubmed/30288417 http://dx.doi.org/10.1177/2381468317697002

Ejemplares similares

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2017)

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

How should we prepare for an outbreak of reintroduced live polioviruses?
por: Thompson, Kimberly M, et al.
Publicado: (2017)

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Another look at silent circulation of poliovirus in small populations
por: Kalkowska, Dominika A., et al.
Publicado: (2018)

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination
por: Kalkowska, Dominika A, et al.
Publicado: (2015)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

An economic analysis of poliovirus risk management policy options for 2013–2052
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)
por: Thompson, Kimberly M., et al.
Publicado: (2019)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge
por: Hird, Thomas R., et al.
Publicado: (2012)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation
por: Thompson, Kimberly M., et al.
Publicado: (2023)

Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine
por: Zhao, Ting, et al.
Publicado: (2021)

Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks()
por: Estivariz, Concepcion F., et al.
Publicado: (2023)

Potential Future Use, Costs, and Value of Poliovirus Vaccines
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines
por: Alipon, SweetC B, et al.
Publicado: (2022)

Environmental Surveillance of Polioviruses in Armenia, Colombia before Trivalent Oral Polio Vaccine Cessation
por: González, María Mercedes, et al.
Publicado: (2019)

Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation
por: Kalkowska, Dominika A, et al.
Publicado: (2023)

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region
por: Tevi-Benissan, Carol, et al.
Publicado: (2017)

Fractional-dose inactivated poliovirus vaccine, India
por: Haldar, Pradeep, et al.
Publicado: (2019)

III. Factors Influencing the Acceptance of Oral Poliovirus Vaccine
por: Cohart, Edward M., et al.
Publicado: (1962)

Assessing the Risk of Vaccine-derived Outbreaks After Reintroduction of Oral Poliovirus Vaccine in Postcessation Settings
por: Fu, Rui, et al.
Publicado: (2018)

A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vr2ggteemoj5225tsqls6gfuqu